Evidence map›Paper›PMID 31728915›Full record

ReviewAdvances in experimental medicine and biology2020

Gene Editing in Human Pluripotent Stem Cells: Recent Advances for Clinical Therapies.

Hatice Burcu Şişli, Taha Bartu Hayal, Selin Seçkin, Selinay Şenkal, Binnur Kıratlı, Fikrettin Şahin, Ayşegül Doğan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hatice Burcu ŞişliDepartment of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Istanbul, Turkey.
Taha Bartu HayalDepartment of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Istanbul, Turkey.
Selin SeçkinDepartment of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Istanbul, Turkey.
Selinay ŞenkalDepartment of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Istanbul, Turkey.
Binnur KıratlıDepartment of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Istanbul, Turkey.
Fikrettin ŞahinDepartment of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Istanbul, Turkey.
Ayşegül DoğanDepartment of Genetics and Bioengineering, Faculty of Engineering, Yeditepe University, Istanbul, Turkey. aysegul.dogan@yeditepe.edu.tr.
Yeditepe University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of human embryonic stem cells and reprogramming technology to obtain induced pluripotent stem cells from adult somatic cells have provided unique opportunity to create human disease models, gene editing strategies and cell therapy options.Development of pluripotent stem cells from somatic cells and genomic manipulation tools enabled to use site specific nucleases in the cell therapy research. Identification of efficient gene manipulation, safe differentiation and use will provide a novel strategy to treat many diseases in the near future. Current available registered clinical trials clearly indicate the need for pluripotent stem cell and gene therapy treatment options. Although gene editing based pluripotent stem cell research is a popular field for research worldwide, improvement of clinical approaches for treatment still remains to be investigated. In this review, we summarized the current situation of gene editing based pluripotent cell therapy developments and applications in clinics.

Indexed as

Gene EditingCell- and Tissue-Based TherapyGenetic TherapyHuman Embryonic Stem CellsHumansInduced Pluripotent Stem CellsPluripotent Stem CellsCell therapyClinical trialGene therapyPluripotent stem cellRegenerative medicine

Identifiers

PMID31728915
OpenAlexW2984230491

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.